请使用支持JavaScript的浏览器!
主营:抗癌化学试剂和激酶抑制剂
℡ 4000-520-616
℡ 4000-520-616
MedKoo/Ombrabulin HClfeatured/5mg/200380
产品编号:200380
市  场 价:¥4600.00
场      地:美国(厂家直采)
产品分类: 蛋白类>多肽>多肽合成>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:$230.00
品      牌: MedKoo
公      司:MedKoo Biosciences, Inc
公司分类:
MedKoo/Ombrabulin HClfeatured/5mg/200380
商品介绍

Ombrabulin HCl
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:200380

CAS#:253426-24-3 (HCl)

Description:Ombrabulin is a synthetic water-soluble analogue of combretastatin A4, derived from the South African willow bush (Combretum caffrum), with potential vascular-disrupting and antineoplastic activities. Ombrabulin binds to the colchicine binding site of endothelial cell tubulin, inhibiting tubulin polymerization and inducing mitotic arrest and apoptosis in endothelial cells.

Price and Availability

SizePriceShipping out timeQuantity
5mgUSD 2302 Weeks
25mgUSD 5702 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

Ombrabulin HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 200380Name: Ombrabulin HClCAS#: 253426-24-3 (HCl)Chemical Formula: C21H27ClN2O6Exact Mass: 402.17909Molecular Weight: 438.90188Elemental Analysis: C, 57.47; H, 6.20; Cl, 8.08; N, 6.38; O, 21.87

Related CAS #:253426-24-3 (HCl); 181816-48-8 (free base);

Synonym:AVE8062; AVE8062; AVE8062; AVE-8062A; AC7700; AC-7700; AC 7700; CS-39-L-Ser.HCl; Ombrabulin; Ombrabulin HCl.

IUPAC/Chemical Name:(2S)-2-amino-3-hydroxy-N-[2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide hydrochloride.

InChi Key:UQNRTPFLTRZEIM-MRWUDIQNSA-N

InChi Code:InChI=1S/C21H26N2O6.ClH/c1-26-17-8-7-13(9-16(17)23-21(25)15(22)12-24)5-6-14-10-18(27-2)20(29-4)19(11-14)28-3;/h5-11,15,24H,12,22H2,1-4H3,(H,23,25);1H/b6-5-;/t15-;/m0./s1

SMILES Code:O=C(NC1=CC(/C=CC2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC)[C@@H](N)CO.[H]Cl

Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

Ombrabulin was granted orphan drug status by the European Medicines Agency in April 2011. Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth. .

References

 1: Delmonte A, Sessa C. AVE8062: a newcombretastatin derivative vascular disrupting agent. Expert OpinInvestig Drugs. 2009 Oct;18(10):1541-8. Review. PubMed PMID: 19758109.

2: Hori K, Furumoto S, Kubota K. Tumor blood flow interruption afterradiotherapy strongly inhibits tumor regrowth. Cancer Sci. 2008Jul;99(7):1485-91. Epub 2008 Apr 29. PubMed PMID: 18452559.

3: Cai SX. Small molecule vascular disrupting agents: potential newdrugs for cancer treatment. Recent Pat Anticancer Drug Discov. 2007Jan;2(1):79-101. Review. PubMed PMID: 18221055.

4: Lavisse S, Lejeune P, Rouffiac V, Elie N, Bribes E, Demers B,Vrignaud P, Bissery MC, Brulé A, Koscielny S, Péronneau P, Lassau N.Early quantitative evaluation of a tumor vasculature disruptive agentAVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol.2008 Feb;43(2):100-11. PubMed PMID: 18197062.

5: Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, MerrittWM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL,Kundra V, Sood AK. Antitumor and antivascular effects of AVE8062 inovarian carcinoma. Cancer Res. 2007 Oct 1;67(19):9337-45. PubMed PMID:17909042.

6: Lippert JW 3rd. Vascular disrupting agents. Bioorg Med Chem. 2007 Jan15;15(2):605-15. Epub 2006 Oct 27. PubMed PMID: 17070061.

7: Hori K. Antineoplastic strategy: irreversible tumor blood flow stasisinduced by the combretastatin A-4 derivative AVE8062 (AC7700).Chemotherapy. 2005 Oct;51(6):357-60. Epub 2005 Oct 14. Review. PubMedPMID: 16227690.

8: Thorpe PE. Vascular targeting agents as cancer therapeutics. ClinCancer Res. 2004 Jan 15;10(2):415-27. Review. PubMed PMID: 14760060.

9: Hori K, Saito S. Induction of tumour blood flow stasis and necrosis:a new function for epinephrine similar to that of combretastatin A-4derivative AVE8062 (AC7700). Br J Cancer. 2004 Jan 26;90(2):549-53.PubMed PMID: 14735207; PubMed Central PMCID: PMC2409553.

10: Hori K, Saito S. Microvascular mechanisms by which thecombretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flowstasis. Br J Cancer. 2003 Oct 6;89(7):1334-44. PubMed PMID: 14520469;PubMed Central PMCID: PMC2394288.

品牌介绍
MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(Research Triangle Park, 简称 RTP ),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸
自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔